Skip to main content
Jun 21, 2021

Crinetics appoints first general counsel

Garlan Adams was previously an adviser to Indivior

Nasdaq-listed Crinetics Pharmaceutical has hired Garlan Adams to fill the newly created position of general counsel.

Adams was previously an adviser to Indivior on a range of compliance and litigation matters related to product commercialization including patient access, interactions with healthcare professionals, sales, marketing and product life-cycle issues.

Before that, she was general counsel at Avanir Pharmaceuticals, a role in which she advised on matters related to compliance, clinical-stage development, sales, marketing, pricing and distribution, in addition to developing contracting processes and policies.

Earlier in her career, Adams worked at Eli Lilly & Company, Amylin Pharmaceuticals, Amgen and Onyx Pharmaceuticals, where she provided counsel on product labeling, launch readiness, medical affairs, manufacturing, sales, marketing, pricing and compliance.

Crinetics is a clinical-stage pharmaceutical company focused on novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Scott Struthers, founder and CEO, says in a statement: ‘Garlan has devoted her career to advising large and small pharmaceutical companies on the complexities of intellectual property [and] regulatory and compliance matters related to the development of therapeutics for the US and international markets. I am confident that having Garlan’s breadth of legal experience in clinical development and commercialization will be a tremendous asset to Crinetics.’

 

Ben Maiden

Ben Maiden is the editor-at-large of Governance Intelligence, an IR Media publication, having joined the company in December 2016. He is based in New York. Ben was previously managing editor of Compliance Reporter, covering regulatory and compliance...